Antioxidants in male infertility: from empirical supplementation to phenotype directed therapy
- 1School of Health and Nursing, Wuchang University of Technology
- 2The Reproduction Medical Center, Shenzhen Luohu People’s Hospital, Shantou University Medical College
- 3The Third Affiliated Hospital of Shenzhen University, Shenzhen University
Abstract
Oxidative stress is a biologically plausible contributor to male infertility, and antioxidant supplementation has been investigated for decades. Yet clinical evidence has not converged on a reproducible benefit in reproductive outcomes. The 2025 World Health Organization (WHO) infertility guideline made no recommendation for or against antioxidant supplementation in men with infertility and one or more semen parameters outside WHO reference ranges, reflecting uncertainty rather than proof of universal inefficacy. A Cochrane review identified 90 randomized controlled trials involving 10,303 men, but live birth was reported in only 12 trials with very low certainty. Contemporary randomized trials have not resolved the uncertainty: MOXI found no improvement in semen parameters, sperm DNA fragmentation, pregnancy, or live birth with a multicomponent antioxidant formulation; FAZST found no benefit of folic acid and zinc on semen quality or live birth with an increase in sperm DNA fragmentation; and SUMMER found no improvement in ongoing pregnancy with a combined antioxidant supplement. These findings make routine empirical supplementation difficult to justify but do not establish universal inefficacy of redox modulating interventions. Most trials have enrolled men according to clinical infertility or semen criteria rather than a prospectively defined standardized redox phenotype and have rarely tested treatment effect modification. Biological and clinical heterogeneity, differences among interventions, physiological roles of reactive oxygen species, and reliance on surrogate endpoints may dilute true effects. Future trials should determine which biologically defined men, if any, benefit from which redox modulating intervention, using standardized phenotyping, target engagement measures, prespecified treatment by phenotype interaction testing, and clinically meaningful reproductive outcomes.
Related
- A Case Report Series on Supplementation with 1100 mg Myo-Inositol/ 300 mg D-Chiro-Inositol (3.6:1 Ratio), Antioxidants and Probiotics to Improve Oocyte Quality and Increase Pregnancy Chances in Women With History of ART Failures Without PCOS
- Phenotype-informed selection of microbiota-directed interventions in irritable bowel syndrome: current evidence and limitations
- Valorization of Watermelon Peel Flavonoids: Kaempferol, Quercetin, and Rutin as Natural Antioxidants for Functional Food and Nutraceutical Applications
- Special Issue “The Role of Oxidative Stress and Antioxidants in Human Disease”
- Rhodanine and 2,4-dioxothiazolidine-based amides: synthesis and evaluation as dual-action cholinesterase inhibitors and antioxidants.
BibTeX
@article{zafar2026antioxidants,
title = {{Antioxidants in male infertility: from empirical supplementation to phenotype directed therapy}},
author = {Mohammad Ishraq Zafar and Mengyuan Qu},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1971018},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1971018/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Antioxidants in male infertility: from empirical supplementation to phenotype directed therapy
AU - Mohammad Ishraq Zafar
AU - Mengyuan Qu
PY - 2026
DA - 2026/10/13
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1971018
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1971018/full
AB - Oxidative stress is a biologically plausible contributor to male infertility, and antioxidant supplementation has been investigated for decades. Yet clinical evidence has not converged on a reproducible benefit in reproductive outcomes. The 2025 World Health Organization (WHO) infertility guideline made no recommendation for or against antioxidant supplementation in men with infertility and one or more semen parameters outside WHO reference ranges, reflecting uncertainty rather than proof of universal inefficacy. A Cochrane review identified 90 randomized controlled trials involving 10,303 men, but live birth was reported in only 12 trials with very low certainty. Contemporary randomized trials have not resolved the uncertainty: MOXI found no improvement in semen parameters, sperm DNA fragmentation, pregnancy, or live birth with a multicomponent antioxidant formulation; FAZST found no benefit of folic acid and zinc on semen quality or live birth with an increase in sperm DNA fragmentation; and SUMMER found no improvement in ongoing pregnancy with a combined antioxidant supplement. These findings make routine empirical supplementation difficult to justify but do not establish universal inefficacy of redox modulating interventions. Most trials have enrolled men according to clinical infertility or semen criteria rather than a prospectively defined standardized redox phenotype and have rarely tested treatment effect modification. Biological and clinical heterogeneity, differences among interventions, physiological roles of reactive oxygen species, and reliance on surrogate endpoints may dilute true effects. Future trials should determine which biologically defined men, if any, benefit from which redox modulating intervention, using standardized phenotyping, target engagement measures, prespecified treatment by phenotype interaction testing, and clinically meaningful reproductive outcomes.
SN - 1664-2392
ER -